arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

CervoMed Inc.

CRVO
$2.53 ▼ -0.02 (-0.78%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
58 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

CervoMed Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $25.9M
Dividend Yield
Revenue Growth N/M
Op. Margin None
ROIC -23.0%
FCF / Share $-0.68
Trailing P/E
Price / Book 1.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

58-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-6.57M
↓ -5.0%
Operating Margin Operating profit as % of sales
-376.4%
↓ -36.1%
FCF / Share Free cash flow per share
$-0.68
↑ +22.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
5
Cash Quality
59

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 14 years · 58 quarters